RSF Bio's Therapeutic Solutions
Ataciguat
Ataciguat is a small molecule drug developed to slow the progression of CAVS and delay surgical valve replacement.
Market Need for Non-Invasive CAVS Treatment
Since CAVS is a common valvular disease in the elderly, the market for ataciguat is approximately 2 million people in the U.S., over 3 million in Europe, and potentially more throughout the rest of the world.
Future Applications
RSF Bio is engaged in discussions for the licensing in, and the development of, next generation technology for additional applications in the field of cardiovascular disease. Please visit our Science and Pipeline pages for more information.